The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure:a randomized controlled trial (Empire HF Biomarker)

Autor: Massar Omar, Jesper Jensen, Caroline Kistorp, Kurt Højlund, Lars Videbæk, Christian Tuxen, Julie H. Larsen, Camilla F. Andersen, Finn Gustafsson, Lars Køber, Morten Schou, Jacob Eifer Møller

Publikováno v: Omar, M, Jensen, J, Kistorp, C, Højlund, K, Videbæk, L, Tuxen, C, Larsen, J H, Andersen, C F, Gustafsson, F, Køber, L, Schou, M & Møller, J E 2022, ' The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure : a randomized controlled trial (Empire HF Biomarker) ', Cardiovascular Diabetology, vol. 21, 34 . https://doi.org/10.1186/s12933-022-01463-2
Omar, M, Jensen, J, Kistorp, C, Højlund, K, Videbæk, L, Tuxen, C, Larsen, J H, Andersen, C F, Gustafsson, F, Køber, L, Schou, M & Møller, J E 2022, ' The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure : a randomized controlled trial (Empire HF Biomarker) ', Cardiovascular Diabetology, vol. 21, no. 1, 34 . https://doi.org/10.1186/s12933-022-01463-2

Background Plasma growth differentiation factor-15 (GDF-15) biomarker levels increase in response to inflammation and tissue injury, and increased levels of GDF-15 are associated with increased risk of mortality in patients with heart failure with re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2b6a6412bbe3d1e4c11f80b5b70b561
https://findresearcher.sdu.dk:8443/ws/files/199867422/s12933_022_01463_2_1_.pdf

Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)

Autor: Finn Gustafsson, Emil L. Fosbøl, Mikael Kjær Poulsen, Christian Tuxen, Caroline Kistorp, Morten Schou, Lars Videbæk, Ida Gustafsson, Peter H. Frederiksen, Lars Køber, Jesper Jensen, Niels Eske Bruun, Massar Omar, Jacob E. Møller

Publikováno v: Trials, Vol 20, Iss 1, Pp 1-8 (2019)
Jensen, J, Omar, M, Kistorp, C, Poulsen, M K, Tuxen, C, Gustafsson, I, Køber, L, Gustafsson, F, Fosbøl, E, Bruun, N E, Videbæk, L, Frederiksen, P H, Møller, J E & Schou, M 2019, ' Empagliflozin in heart failure patients with reduced ejection fraction : a randomized clinical trial (Empire HF) ', Trials, vol. 20, 374 . https://doi.org/10.1186/s13063-019-3474-5
Jensen, J, Omar, M, Kistorp, C, Poulsen, M K, Tuxen, C, Gustafsson, I, Køber, L, Gustafsson, F, Fosbøl, E, Bruun, N E, Videbæk, L, Frederiksen, P H, Møller, J E & Schou, M 2019, ' Empagliflozin in heart failure patients with reduced ejection fraction : a randomized clinical trial (Empire HF) ', Trials, vol. 20, no. 1, 374 . https://doi.org/10.1186/s13063-019-3474-5
Trials
Jensen, J, Omar, M, Kistorp, C, Poulsen, M K, Tuxen, C, Gustafsson, I, Køber, L, Gustafsson, F, Fosbøl, E, Bruun, N E, Videbæk, L, Frederiksen, P H, Møller, J E & Schou, M 2019, ' Empagliflozin in heart failure patients with reduced ejection fraction : A randomized clinical trial (Empire HF) ', Trials, vol. 20, 374 . https://doi.org/10.1186/s13063-019-3474-5

Background Data from recent cardiovascular outcome trials in patients with type 2 diabetes (T2D) suggest that sodium-glucose cotransporter 2 (SGLT2) inhibitors can prevent development of heart failure (HF) and prolong life in patients without HF. Ong

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4c6304528bc49f4a5df6af158cfe1ff
http://link.springer.com/article/10.1186/s13063-019-3474-5

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

Autor: David C. Wheeler, Tom Greene, John J.V. McMurray, Hiddo J.L. Heerspink, Robert D. Toto, Anna Maria Langkilde, Glenn M. Chertow, Bergur V. Stefánsson, Fan Fan Hou, Ricardo Correa-Rotter, Dapa-Ckd Trial Committees, Investigators, Peter Rossing, C. David Sjöström, Niels Jongs

Publikováno v: Lancet Diabetes & Endocrinology, 9(1), 22-31. ELSEVIER SCIENCE INC
DAPA-CKD Trial Committees and Investigators 2021, ' Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease : a prespecified analysis from the DAPA-CKD trial ', The Lancet Diabetes and Endocrinology, vol. 9, no. 1, pp. 22-31 . https://doi.org/10.1016/S2213-8587(20)30369-7

Background: Dapagliflozin reduces the risk of kidney failure and heart failure in patients with chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney, cardiovascular, and mortality outcomes according to presence or ab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a3a1159f26d848e4b231091b2729525
https://research.rug.nl/en/publications/92ee2074-5922-4044-aceb-cfcbddfff59c

Comparison of Pregnancy and Lactation Labeling for Attention-Deficit Hyperactivity Disorder Drugs Marketed in Australia, the USA, Denmark, and the UK

Autor: Pernille Warrer, Lise Aagaard, Ebba Holme Hansen

Publikováno v: Warrer, P, Aagaard, L & Holme Hansen, E 2014, ' Comparison of Pregnancy and Lactation Labeling for Attention-Deficit Hyperactivity Disorder Drugs Marketed in Australia, the USA, Denmark, and the UK ', Drug Safety, vol. 37, no. 10, pp. 805-813 . https://doi.org/10.1007/s40264-014-0215-2

Pregnancy and lactation labeling is presented in the officially recognized product information (PI) accompanying prescription drugs to ensure appropriate prescribing in pregnant and breastfeeding women. The aim of this study was to analyze pregnancy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb3868864a9a75a4defb4d1b3faee25f
https://doi.org/10.1007/s40264-014-0215-2

Effect of modafinil on subjective fatigue in multiple sclerosis and stroke patients

Autor: Brioschi, Andrea, Gramigna, Sandrine, Werth, Esther, Staub, Fabienne, Ruffieux, Christiane, Bassetti, Claudio, Schluep, Myriam, Annoni, Gian-Maria

Publikováno v: European Neurology, Vol. 62, No 4 (2009) pp. 243-249

BACKGROUND: Modafinil has anecdotal response to neurological fatigue, but such an effect may depend on the type and location of cerebral impairment. OBJECTIVES: It was the aim of this study to compare fatigue observed in different neurological pathol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1400::b42979b42633bf54371d9f2ef5fb6dbe
https://archive-ouverte.unige.ch/unige:19708